Edition:
United Kingdom

Biofrontera AG (B8FGn.DE)

B8FGn.DE on Xetra

6.52EUR
4:36pm BST
Change (% chg)

€0.12 (+1.88%)
Prev Close
€6.40
Open
€6.39
Day's High
€6.55
Day's Low
€6.36
Volume
60,788
Avg. Vol
35,137
52-wk High
€6.58
52-wk Low
€4.78

Latest Key Developments (Source: Significant Developments)

Biofrontera Q1 Prelim Revenue At About EUR 6.8 Million
Monday, 15 Apr 2019 

April 15 (Reuters) - Biofrontera AG ::DGAP-NEWS: BIOFRONTERA AG: BIOFRONTERA REPORTS PRELIMINARY UNAUDITED SALES REVENUE FOR THE FIRST THREE MONTHS OF 2019.PRELIMINARY UNAUDITED REVENUE OF COMPANY FOR PERIOD JANUARY TO MARCH 2019 WAS AROUND EUR 6.8 MILLION.Q1 PRELIMINARY UNAUDITED PRODUCT SALES IN U.S. ARE EXPECTED TO BE ABOUT EUR 5.2 MILLION, VERSUS EUR 3.4 MILLION YEAR AGO.  Full Article

Biofrontera: Information On Announced Voluntary Public Tender Offer By Maruho Deutschland
Tuesday, 2 Apr 2019 

April 2 (Reuters) - BIOFRONTERA AG ::BIOFRONTERA PROVIDES INFORMATION ON ANNOUNCED VOLUNTARY PUBLIC TENDER OFFER BY MARUHO DEUTSCHLAND GMBH.MANAGEMENT BOARD OF BIOFRONTERA AG VALUES MARUHO AS A STRATEGICALLY ORIENTED LONG-TERM PARTNER.MARUHO TO OFFER TO SHAREHOLDERS OF BIOFRONTERA AG TO ACQUIRE A TOTAL OF UP TO 4,322,530 NO-PAR VALUE REGISTERED SHARES.ACQUISITION AGAINST PAYMENT OF EUR 6.60 PER SHARE IN CASH.BIOFRONTERA - MANAGEMENT BOARD REGARDS MARUHO'S INTEREST IN INCREASE IN ITS SHAREHOLDING AS AFFIRMATION OF PATH IT HAS TAKEN TO MAKE BIOFRONTERA A LEADING SPECIALIST IN DERMATOLOGY.  Full Article

Biofrontera Receives FDA Approval For Upscaling Of Batch Size For Ameluz(R) Production
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - BIOFRONTERA AG ::RECEIVES FDA APPROVAL FOR UPSCALING OF BATCH SIZE FOR AMELUZ(R) PRODUCTION.SAYS US FDA AND EUROPEAN MEDICINES AGENCY APPROVED UPSCALING OF BATCH SIZE FOR PRODUCTION OF AMELUZ^(R) TO 35 KG FROM PREVIOUSLY 7 KG.FDA-APPROVAL IS EFFECTIVE JANUARY 3, 2019.  Full Article

Biofrontera Publishes Review Of Capital Increase In February 2018
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Biofrontera AG ::PUBLISHES THE RESULT OF THE INDEPENDENT REVIEW OF THE CAPITAL INCREASE IN FEBRUARY 2018.SAYS REVIEW CONCLUDES ALLEGATIONS OF ILLEGITIMACY REGARDING BIOFRONTERA'S FEBRUARY 2018 CAPITAL INCREASE ARE UNFOUNDED.  Full Article

Biofrontera: Swissmedic Approves Ameluz In Combination With Daylight Photodynamic Therapy In Switzerland
Monday, 1 Oct 2018 

Oct 1 (Reuters) - BIOFRONTERA AG ::SWISSMEDIC APPROVES AMELUZ(R) IN COMBINATION WITH DAYLIGHT PHOTODYNAMIC THERAPY IN SWITZERLAND.BIOFRONTERA AND LOUIS WIDMER SEE SALES EFFECT FOR SUMMER MONTHS OF 2019 COMPARABLE TO ONE IN GERMAN MARKET THIS YEAR.  Full Article

Deutsche Balaton Biotech: Offer For Biofrontera Shares To Be Carried Out On Schedule
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Deutsche Balaton Biotech AG::Voluntary Purchase Offer For 6.25 Million Biofrontera <<>> SHARES WILL BE CARRIED OUT ON SCHEDULE.DEUTSCHE BALATON AG BIOTECH AG - AS ALREADY ANNOUNCED, VOLUNTARY OFFER ENDS ON 6TH AUGUST 2018.DEUTSCHE BALATON BIOTECH AG - AS ALREADY ANNOUNCED, VOLUNTARY OFFER ENDS ON 6TH AUGUST 2018.  Full Article

Biofrontera Comments On Tender Offer By Deutsche Balaton
Thursday, 2 Aug 2018 

Aug 3 (Reuters) - Biofrontera AG ::Said on Thursday Comments On Tender Offer By Deutsche Balaton.  Full Article

Biofrontera Rejects Modified Tender Offer Of Deutsche Balaton Biotech AG
Monday, 30 Jul 2018 

July 30 (Reuters) - Biofrontera AG ::BIOFRONTERA ALSO REJECTS MODIFIED TENDER OFFER OF DEUTSCHE BALATON BIOTECH AG.  Full Article

Biofrontera: Management To Give Opinion On Changed Purchase Offer
Friday, 27 Jul 2018 

July 27 (Reuters) - BIOFRONTERA AG ::SEES MANAGEMENT TO GIVE OPINION ON CHANGED PURCHASE OFFER AND ALTERNATIVE CONSIDERATION IN AMOUNT OF CASH PAYMENT OF EUR 6.00.  Full Article

Biofrontera Completes Patient Recruitment For Phase III Trial With Ameluz
Thursday, 26 Jul 2018 

July 26 (Reuters) - BIOFRONTERA AG ::EXPANSION OF INDICATION FOR AMELUZ(R): BIOFRONTERA COMPLETES PATIENT RECRUITMENT FOR PHASE III TRIAL.FILING FOR APPROVAL ANTICIPATED FOR Q3 2019.  Full Article